# Cellenkos

received FDA clearance to initiate a Phase 2 clinical trial of CK0801, an allogeneic cord-blood-derived Treg, for aplastic anaemia, extending Treg therapy beyond oncology into autoimmune haematology.

Source: https://en.bioecon.ru/companies/cellenkos/
Updated: 2026-07-20

- Country: United States

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Funding | $15 million in total funding from a Series A round concluded on November 4, 2021 | https://cellenkosinc.com/news/index.html |
| Production site | Cellenkos Manufacturing Facility (CMF) in Houston, TX | https://cellenkosinc.com/ourscience/index.html |
| Regulatory approval | FDA clearance to initiate Phase 2 clinical trial of CK0801 for aplastic anemia received April 27, 2026 | https://novapharmanews.com/us/news/cellenkos-fda-clearance-ck0801-phase-2-aplastic-anemia-trial, https://www.prnewswire.com/news-releases/cellenkos-inc-announces-fda-clearance-to-initiate-phase-2-clinical-trial-of-ck0801-allogeneic-cord-blood-derived-tregs-for-aplastic-anemia-302754132.html |
| Regulatory approval | FDA Orphan Drug Designation for CK0801 for aplastic anemia granted as of April 14, 2025 | https://synapse.patsnap.com/article/cellenkos-ck0801-receives-fda-orphan-drug-status-for-aplastic-anemia-treatment |
| Revenue | Estimated annual revenue ranges from $1.28 million to $50 million depending on the source reporting, with one specific estimate of $6 million for 2025 [medium confidence] | https://prospeo.io/c/cellenkos-revenue, https://www.adapt.io/company/cellenkos-1 |

Independent sources: adapt.io, novapharmanews.com, prnewswire.com, prospeo.io, synapse.patsnap.com

## Technologies

- [Stem cell therapy for autoimmune disease](https://en.bioecon.ru/technology/stem-cell-therapy-autoimmune/)